Irisin vs Exendin-4
Head-to-head comparison of Irisin (Irisin (FNDC5 cleavage product)) and Exendin-4 (Exendin-4 (synthetic exenatide)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Irisin | Exendin-4 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Irisin (FNDC5 cleavage product) | Exendin-4 (synthetic exenatide) |
| Molecular Weight | ~12.3 kDa | 4186 Da |
| Half-Life | hours | 2.4 hours |
| Amino Acids | 112 | 39 |
| Typical Dose | No approved human dose; research use only | 5-10 mcg twice daily |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 79 | 1800 |
| Research Status | Pre-clinical | Clinical |
Irisin Benefits
- ✓glucose homeostasis
- ✓energy expenditure
- ✓brown-fat activation
Exendin-4 Benefits
- ✓beta-cell survival
- ✓glucose-stimulated insulin secretion
- ✓reduced glucolipotoxicity
- ✓lowered HbA1c in clinical use
Irisin Dosing
not established|not established
Exendin-4 Dosing
5 mcg SC twice daily for 4 weeks|increase to 10 mcg SC twice daily if tolerated|research: 0.1-1 µM in vitro or 1-10 µg/kg in animals
Irisin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Exendin-4 Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠injection-site reactions
Research Overview
Irisin
Irisin is widely explored in obesity and type 2 diabetes research because it connects exercise biology with metabolic adaptation. Human findings are mixed, so it remains a biomarker and preclinical lead rather than an approved therapy.
Exendin-4
Exendin-4 helped establish GLP-1 receptor biology in diabetes and remains a classic beta-cell protective peptide. Preclinical studies show reduced beta-cell apoptosis, improved insulin content, and better islet function under metabolic stress.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.